Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Neuromuscular disease

Patients with refractory myasthenia gravis respond to immunotherapy after cyclophosphamide induction

Nature Reviews Neurology volume 11, page 4 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

A new study suggests that pretreatment with cyclophosphamide can enhance treatment benefit in otherwise refractory patients with myasthenia gravis. Eight patients with myasthenia gravis that was unresponsive to standard therapy received intravenous cyclophosphamide for 6 weeks. Six of the eight patients responded well to standard immunotherapies after cyclophosphamide induction, and four of them remained in remission for over 2 years.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Buzzard, K. A. et al. Induction IV cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 10.1002/mus.24536

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patients with refractory myasthenia gravis respond to immunotherapy after cyclophosphamide induction. Nat Rev Neurol 11, 4 (2015). https://doi.org/10.1038/nrneurol.2014.247

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.247

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing